George Clinical / Emerald Clinical Device Trials vs a Latin America First-in-Human CRO (bioaccess®)

George Clinical (Emerald Clinical) vs bioaccess®: what George Clinical (Emerald Clinical) publishes, where it fits, and when a medical-device first-in-human specialist in Latin America since 2010 is the better tool.

If you typed George Clinical (Emerald Clinical) into a search box, you are probably building a CRO shortlist. This article uses only what George Clinical (Emerald Clinical) publishes (georgesclinical.com/therapeutic-expertise/medical-devices-cro · emeraldclinical.com · emeraldclinical.com/about-us) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

What George Clinical (Emerald Clinical) publishes

George Clinical came out of The George Institute in Australia and in 2025 became Emerald Clinical Trials, which says it is headquartered in Singapore. George Clinical's medical device page covers feasibility, pilot, Class II/III pivotal and post-market studies, and describes it as a specialized CRO in Asia-Pacific and the USA. Emerald says it has completed 600+ trials across 70+ geographies over more than 25 years, with strength in renal, cardiovascular and oncology research.

George Clinical (Emerald Clinical) vs bioaccess®

Dimension George Clinical (Emerald Clinical) bioaccess®
Core focus APAC-origin full-service CRO, late-phase strength First-in-human and early feasibility studies for medical devices
Geography Australia Latin America, since 2010
Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
After the trial Post-market studies and surveillance, plus regulatory and pharmacovigilance services Live multi-country sanitary registration and in-country holder service

Where each one fits

If the device program is a large pivotal or post-market study across Asia-Pacific, George / Emerald is a capable choice.

If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including George Clinical (Emerald Clinical), for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not George Clinical (Emerald Clinical) features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.

Ready to compare a proposal? Request a first-in-human study proposal.

Competitor facts from the George Clinical (Emerald Clinical) public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

← Back to Blog · Contact bioaccess®